Manchester digital agency e3creative have been appointed to create the Global Psoriasis Atlas (GPA) following a competitive tendering process. Fuelled by existing data and future studies, the GPA will be the leading epidemiological resource on psoriasis globally and will be open access to the public and healthcare professionals. In response to a report by the World Health Organisation it is being brought forward as a joint endeavour between the International League of Dermatological Societies (ILDS), the International Psoriasis Council (IPC), and the International Federation of Psoriasis Associations (IFPA).
The GPA appointed e3creative to further the initiative's message, through a dynamic digital strategy, involving the design and development of an informative, universally accessible website.
Founder of e3creative Jake Welsh said: “the findings stemming out of The GPA will be communicated in a humanised way to alter perceptions and unite an international community. By acknowledging the prevalence of psoriasis and the psychosocial and societal repercussions of the condition, a greater sense of understanding and acceptance will follow.’’
“The e3creative platform will blend statistics, personal stories and testimonials to ensure the impact arising out of the research widely resonates and continues to grow as the atlas expands.”
To develop the GPA, researchers at The University of Manchester and the University of Hamburg, in collaboration with ILDS, IPC and IFPA have been conducting an extensive systematic review of published and unpublished data, relating to psoriasis so as to standardise case-definition and methodology. Based on this analysis, researchers will be able to compare the burden of psoriasis and access of patients to the best quality care in any country around the world...
Director of the GPA, Professor Chris Griffiths (Manchester) said: “we are excited about working with e3creative on the Global Psoriasis Atlas, their impressive blend of dynamism, inventiveness and professionalism is a perfect fit with our goals”
For the first time, the Global Psoriasis Atlas will produce a global ‘picture’ of Psoriasis and the disease burden. The programme is funded by pooled grants from dermatological societies, foundations and industry.
The Global Psoriasis Atlas has been supported by grants from LEO foundation and Novartis Pharma AG and has been sponsored by AbbVie and Eli Lilly UK and Company Limited.
